Nitric oxide and peroxynitrite play critical roles in the pathophysiology of hemorrhagic shock, suggesting that inhibiting iNOS or PARS may be potential therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use of iNOS inhibitors in shock; leaves open translation of animal benefits to human trials.
Szabó et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: